| Completed | Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome NCT03359460 | University of California, Davis | Phase 1 |
| Active Not Recruiting | Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute M NCT02890329 | National Cancer Institute (NCI) | Phase 1 |
| Completed | WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or NCT02666950 | Mayo Clinic | Phase 2 |
| Terminated | Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic NCT03146871 | University of Southern California | Phase 2 |
| Recruiting | A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemi NCT03017820 | Mayo Clinic | Phase 1 |
| Completed | Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS NCT02921061 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grad NCT02756572 | University of Washington | Phase 2 |
| Recruiting | Personalized NK Cell Therapy in CBT NCT02727803 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome NCT02553941 | Brian Jonas | Phase 1 |
| Completed | Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelo NCT02446964 | City of Hope Medical Center | Phase 1 |
| Suspended | Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With R NCT02333162 | University of Chicago | Phase 1 |
| Recruiting | Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk NCT02115295 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies NCT02129101 | Mayo Clinic | Phase 1 |
| Completed | Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in R NCT02083250 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed o NCT02044796 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT01664897 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapse NCT01729845 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloi NCT01757639 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgra NCT01624805 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With NCT01300572 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT01130506 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia NCT01132586 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High- NCT00988715 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by NCT00789776 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Terminated | Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Dono NCT00589316 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, NCT00453388 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonoc NCT00313586 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases NCT00351975 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia NCT00357565 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blast NCT00217646 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease i NCT00105001 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Tr NCT00027820 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |